PolyPid Ltd. (PYPD)

$6.31

+0.10 (+1.61%)
Rating:
Recommendation:
-
Symbol PYPD
Price $6.31
Beta 0.896
Volume Avg. 0.02M
Market Cap 123.368M
Shares () -
52 Week Range 3.92-9.64
1y Target Est -
DCF Unlevered PYPD DCF ->
DCF Levered PYPD LDCF ->
ROE -107.05% Strong Sell
ROA -128.29% Strong Sell
Operating Margin -
Debt / Equity 23.01% Neutral
P/E -
P/B 4.14 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PYPD news


Mr. Amir Weisberg
Healthcare
Biotechnology
NASDAQ Global Market

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.